Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida

Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida

Introduction: The new direct acting antivirals (DAA) have demonstrated low rates of adverse effects in controlled studies. However, real world-studies have disclosed emerging toxicities and drug-drug interactions in special populations. Methods: We conducted a retrospective review of HIV/HCV coinfec...

Full description

Bibliographic Details
Main Author:	Jose Armando Gonzales Zamora
Format:	Article
Language:	English
Published:	MDPI AG 2018-06-01
Series:	Diseases
Subjects:	adverse effects Hepatitis C HIV direct acting antivirals
Online Access:	http://www.mdpi.com/2079-9721/6/2/51

Similar Items

Evolution of Pretreatment Assessment and Direct Acting Antiviral Regimens in Accordance with Upgrading Guidelines: A Retrospective Study in HIV/HCV Coinfected Patients
by: Zachary Henry, et al.
Published: (2018-09-01)

Evaluation of direct-acting antivirals and antiretroviral therapy for HIV-HCV coinfected patients in the United States
by: Rivera, Josef Kyle Concepcion
Published: (2021)

The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV–HCV Coinfection
by: Leigh P. Johnson, et al.
Published: (2020-04-01)

Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
by: Nancy Abdel Fattah Ahmed, et al.
Published: (2020-08-01)

A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome
by: Sabrina Bagaglio, et al.
Published: (2020-02-01)

Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
by: A. Maughan, et al.
Published: (2019-05-01)

A Tale of Two Viruses: Immunological Insights Into HCV/HIV Coinfection
by: Samaa T. Gobran, et al.
Published: (2021-08-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

Assessment of Renal Function in Post-Liver Transplant HCV-Positive Patients Treated with Direct Acting Antivirals
by: Elzorkany K, et al.
Published: (2020-11-01)

Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis
by: S N Batskikh, et al.
Published: (2018-11-01)

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
by: Giuseppe Bruno, et al.
Published: (2017-09-01)

What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis
by: Britt Skaathun, et al.
Published: (2020-08-01)

Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients
by: Curtis L. Cooper, et al.
Published: (2017-11-01)

HCV-Specific T Cell Responses During and After Chronic HCV Infection
by: Hendrik Luxenburger, et al.
Published: (2018-11-01)

Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis
by: Chih-Chin Kao, et al.
Published: (2018-09-01)

Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study
by: Luz Maria Medrano, et al.
Published: (2021-02-01)

Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection
by: Olea Jr A, et al.
Published: (2018-08-01)

Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals
by: Tatsuya Minami, et al.
Published: (2021-06-01)

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
by: Chung-Feng Huang, et al.
Published: (2020-07-01)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
by: Andrea Angeletti, et al.
Published: (2019-02-01)

Effect of Successful Direct Acting Antivirals Therapy on Liver Stiffness in Patients with Chronic HCV Infection
by: Ibrahim Anam Ezzelregal, et al.
Published: (2020-10-01)

Direct-acting antivirals and visceral leishmaniasis: a case report
by: Claudia Colomba, et al.
Published: (2019-04-01)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
by: Asma Ahmed, et al.
Published: (2015-12-01)

Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence
by: Fabrizio Fabrizi, et al.
Published: (2019-10-01)

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
by: Soon Young Ko, et al.
Published: (2018-12-01)

Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis
by: Christiana Graf, et al.
Published: (2020-08-01)

Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection—A brief review of literature
by: Mohit Bhatia, et al.
Published: (2020-01-01)

Expanding reimbursement of immediate treatment using direct acting antivirals to reduce hepatitis C incidence among HIV positive men who have sex with men in Bangkok, Thailand: A cost effectiveness modelling study
by: Shreoshee Mukherjee, et al.
Published: (2021-06-01)

Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India
by: Varun Gupta, et al.
Published: (2017-01-01)

Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
by: Mohamed M Sakr, et al.
Published: (2019-01-01)

Chronic Hepatitis C Treatment with New Antiviral Agents
by: Özlem KANDEMİR
Published: (2018-12-01)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
by: Elfi Egmond, et al.

Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs
by: Allan Peres-da-Silva, et al.
Published: (2012-03-01)

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence
by: Nevine Ibrahim Musa, et al.
Published: (2020-07-01)

Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil
by: Vinicius Lins Ferreira, et al.

Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases
by: Nicola Imperatore, et al.
Published: (2017-11-01)

Role of different direct-acting antiviral drugs on hepatitis C virus-associated mixed cryoglobulinemia in Egyptian patients
by: Tarek A Elshazly, et al.
Published: (2019-01-01)

Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection
by: Pil Soo Sung, et al.
Published: (2021-01-01)

High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C
by: Andrew Hill, et al.
Published: (2017-10-01)

The efficacy and safety of direct-acting antiviral agents in patients with chronic HCV infection and UGT1A1*28 polymorphism
by: Lukashyk S.P., et al.
Published: (2020-03-01)